Sihuan Pharmaceutical (HKSE:00460) is one of the largest domestic drug companies in China as well as a leading cardio-cerebral vascular prescription drug franchise by market share. The company enjoys a diversified product mix, in which its fast-growing exclusive drugs will likely face limited pricing pressure. We expect the comp any to likely see further growth with rising demand from a demographic more susceptible to stroke-related conditions. Its extensive agent distribution network is expected to support continued strong sales, in particular their fast-growing drug products manufactured to treat cerebral damage.
From Value Partners (Trades, Portfolio)’ Classic Fund Second Quarter 2014 Commentary.
